Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach

Journal of Virology

Volumn 85, Issue 5, 2011, Pages 2004-2011

  Chattopadhyay, Anasuya ^a   Rose, John K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN F; NEUTRALIZING ANTIBODY; THROMBOSPONDIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ARTICLE; CONTROLLED STUDY; DEFECTIVE VIRUS; MOUSE; NIPAH VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE CULTURE CELL; VACCINE PRODUCTION; VESICULAR STOMATITIS VIRUS; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS REPLICATION;

ANIMALS; CELL LINE; DEFECTIVE VIRUSES; FEMALE; GENE EXPRESSION; GENETIC COMPLEMENTATION TEST; GENETIC VECTORS; HENIPAVIRUS INFECTIONS; HUMANS; MICE; MICE, INBRED BALB C; NIPAH VIRUS; VESICULOVIRUS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; VIRUS REPLICATION;

ANIMALIA; MUS; NIPAH VIRUS; PARAMYXOVIRIDAE; VESICULAR STOMATITIS VIRUS;

EID: 79551717937     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01852-10     Document Type: Article

References (37)

1. Burns, J. C., T. Friedmann, W. Driever, M. Burrascano, and J. K. Yee. 1993. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U. S. A. 90:8033-8037.
2. + cells are required at the time of challenge for optimal protection. Vaccine 26:6329-6337.
3. Chua, K. B., et al. 2000. Nipah virus: a recently emergent deadly paramyxovirus. Science 288:1432-1435. (Pubitemid 30366331)
4. Chua, K. B., et al. 2002. Isolation of Nipah virus from Malaysian Island flying-foxes. Microbes Infect. 4:145-151. (Pubitemid 34183487)
5. Clarke, D. K., et al. 2007. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J. Virol. 81:2056-2064. (Pubitemid 46214477)
6. Diederich, S., M. Moll, H. D. Klenk, and A. Maisner. 2005. The Nipah virus fusion protein is cleaved within the endosomal compartment. J. Biol. Chem. 280:29899-29903.
7. Eaton, B. T., C. C. Broder, and L. F. Wang. 2005. Hendra and Nipah viruses: pathogenesis and therapeutics. Curr. Mol. Med. 5:805-816.
8. Enserink, M. 2004. Emerging infectious diseases. Nipah virus (or a cousin) strikes again. Science 303:1121.
9. Fuerst, T. R., E. G. Niles, F. W. Studier, and B. Moss. 1986. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. U. S. A. 83:8122-8126.
10. Geisbert, T. W., et al. 2006. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 193:1650-1657.
11. Guillaume, V., et al. 2004. Nipah virus: vaccination and passive protection studies in a hamster model. J. Virol. 78:834-840. (Pubitemid 38067605)
12. Gurley, E. S., et al. 2007. Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg. Infect. Dis. 13:1031-1037.
13. Halpin, K., and B. A. Mungall. 2007. Recent progress in henipavirus research. Comp. Immunol. Microbiol. Infect. Dis. 30:287-307.
14. Hsu, V. P., et al. 2004. Nipah virus encephalitis reemergence, Bangladesh. Emerg. Infect. Dis. 10:2082-2087.
15. Jones, S. M., et al. 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11:786-790.
16. Kahn, J. S., A. Roberts, C. Weibel, L. Buonocore, and J. K. Rose. 2001. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J. Virol. 75:11079-11087.
17. Kaku, Y., et al. 2009. A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein. J. Virol. Methods 160:7-13.
18. Kapadia, S. U., et al. 2005. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340:174-182. (Pubitemid 41317492)
19. Kapadia, S. U., I. D. Simon, and J. K. Rose. 2008. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. Virology 376:165-172.
20. Lamb, R. A., and D. Kolakofsky. 1996. Paramyxoviridae: the viruses and their replication, p. 1177-1204. In D. M. Knipe et al. (ed.), Fields virology, 3rd ed. Lippincott Raven Publishers, Philadelphia, PA.
21. Lawson, N. D., E. A. Stillman, M. A. Whitt, and J. K. Rose. 1995. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. U. S. A. 92:4477-4481.
22. Lefrancois, L., and D. S. Lyles. 1982. The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies. Virology 121:157-167.
23. Mungall, B. A., et al. 2006. Feline model of acute Nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J. Virol. 80:12293-12302. (Pubitemid 44904379)
24. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193-199.
25. Okuma, K., et al. 2001. Analysis of the molecules involved in human T-cell leukaemia virus type 1 entry by a vesicular stomatitis virus pseudotype bearing its envelope glycoproteins. J. Gen. Virol. 82:821-830.
26. Publicover, J., E. Ramsburg, and J. K. Rose. 2005. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J. Virol. 79:13231-13238.
27. Roberts, A., L. Buonocore, R. Price, J. Forman, and J. K. Rose. 1999. Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 73:3723-3732.
28. Roberts, A., et al. 1998. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J. Virol. 72:4704-4711. (Pubitemid 28215645)
29. Rose, N. F., et al. 2001. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106:539-549. (Pubitemid 32879316)
30. Schnell, M. J., L. Buonocore, M. A. Whitt, and J. K. Rose. 1996. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J. Virol. 70:2318-2323.
31. Schnell, M. J., J. E. Johnson, L. Buonocore, and J. K. Rose. 1997. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 90:849-857.
32. Schwartz, J. A., et al. 2007. Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology 366:166-173. (Pubitemid 47314403)
33. Tamin, A., et al. 2002. Functional properties of the fusion and attachment glycoproteins of Nipah virus. Virology 296:190-200.
34. Tamin, A., et al. 2009. Development of a neutralization assay for Nipah virus using pseudotype particles. J. Virol. Methods 160:1-6.
35. Weingartl, H. M., et al. 2006. Recombinant Nipah virus vaccines protect pigs against challenge. J. Virol. 80:7929-7938. (Pubitemid 44182294)
36. Witko, S. E., et al. 2010. Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression. J. Virol. Methods 164:43-50.
37. Wong, P. K. Y., A. F. Holloway, and D. V. Cormack. 1971. A search for recombination between temperature-sensitive mutants of vesicular stomatitis virus. J. Gen. Virol. 13:477-479.